What Researchers Did
Researchers conducted a preliminary randomized clinical study to evaluate the use of misonidazole in advanced head and neck cancer patients.
What They Found
In a randomized study using large fractions of irradiation, misonidazole appeared to confer no advantage for advanced head and neck cancer. However, misonidazole was possibly useful in previously (partially) treated patients, and the combination of hyperbaric oxygen and misonidazole did not appear to be toxic.
What This Means for Canadian Patients
For Canadian patients with advanced head and neck cancer, this preliminary study suggests misonidazole may not offer a benefit when combined with large-fraction irradiation. However, it might warrant further investigation for those previously treated, though more definitive research is needed before clinical application.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada or by Canadian researchers.
Study Limitations
This was a preliminary study with limited data, and the abstract uses cautious language, indicating the need for further, more definitive research.